Reduction of Experimental Cerebral Malaria and Its Related Proinflammatory Responses by the Novel Liposome-Based β-Methasone Nanodrug

Table 1

ECM rates after treatment of PbA-infected mice with nSSL-BMS.

Group*	^aECM	SM	Survival on day; 8 after inoculation
Control	38^b; (95%)	2; (5%)	2/40; (5%)
Empty liposomes	12; (100%)	0; (0%)	0/12; (0%)
nSSL-BMS	2; (6.5%)	29; (93.5%)	29/31; (93.5%)

All results depict significant differences relating to experimental cerebral malaria (ECM) versus severe anemic malaria (SM) and nSSL-BMS versus control groups.
*Cumulative results of three experiments.
^aMice were euthanized when signs indicated the onset of irreversible disease.
^bNumber of mice in the group.